/CHMMF

CHMMF Stock - Chimeric Therapeutics Limited

Q: What is the analyst price target for CHMMF?

Analyst price target information is not currently available for CHMMF.

Q: What is CHMMF's market cap?

Market capitalization information is not currently available for CHMMF.

Healthcare|Biotechnology|OTC

$0.00+0.00%

+$0.00 (+0.00%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.00

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for CHMMF

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2021

FY2022

FY2023

FY2024

FY2025

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.56

52W High$0.00

52W Low$0.00

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	$3.97M	N/A	$4.51M	$2.62M	N/A
Gross Profit	$3.12M	$-3,922	$4.51M	$1.67M	$-846,960
Gross Margin	78.7%	N/A	100.0%	63.7%	N/A
Operating Income	$-15,111,460	$-20,719,200	$-25,077,790	$-15,092,488	$-15,107,834
Net Income	$-10,430,424	$-12,529,849	$-25,500,384	$-15,898,400	$-15,113,711
Net Margin	-262.8%	N/A	-566.0%	-607.5%	N/A
EPS	$-0.01	$-0.02	$-0.06	$-0.04	$-0.05

Company Overview

Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies in oncology in Australia. The company develops CHM 0201 (core NK platform) that is in phase I clinical trial for treating solid tumors and hematological malignancies; and CHM 1101 (CLTX CAR T), which is in phase I clinical trial for treating patients with MMP2+ recurrent or progressive glioblastoma. It is also developing CHM 0301 for blood cancers; CHM 1301 (CLTX CAR NK) and CHM 2301 (CDH17 CAR NK) for solid tumors; CHM 1101 (CLTX CAR T) for melanoma, colorectal, and prostate; and CHM 2101 (CDH17 CAR T) for neuroendocrine, colorectal, pancreatic, and gastric. The company was incorporated in 2020 and is based in Carlton, Australia.

Visit Website

Earnings History & Surprises

CHMMF

Beat Rate

100%

Last 4 quarters

Avg Surprise

+56.3%

EPS vs Estimate

Beats / Misses

4/0

Last 12 quarters

Latest EPS

$-0.00

Q1 2025

EPS Surprise History

Q3 21

No data

Q1 22

No data

Q3 22

No data

Q1 23

+63.8%

$-0.01vs$-0.03

Q2 23

+15.5%

$-0.01vs$-0.01

Q2 24

+123.0%

$0.00vs$-0.01

Q3 24

+23.0%

$-0.01vs$-0.02

Q1 25

No data

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q1 2026	Feb 26, 2026	—	—	—	—
Q1 2025	Feb 26, 2025	—	$-0.00	—	—
Q3 2024	Aug 30, 2024	$-0.02	$-0.01	+23.0%	✓ BEAT
Q2 2024	Apr 30, 2024	$-0.01	$0.00	+123.0%	✓ BEAT
Q2 2023	Jun 30, 2023	$-0.01	$-0.01	+15.5%	✓ BEAT
Q1 2023	Feb 28, 2023	$-0.03	$-0.01	+63.8%	✓ BEAT
Q3 2022	Sep 30, 2022	—	$-0.01	—	—
Q1 2022	Feb 27, 2022	—	$-0.02	—	—
Q3 2021	Aug 30, 2021	—	$-0.03	—	—
Q1 2021	Feb 26, 2021	—	$-0.01	—	—
Q2 2020	Jun 30, 2020	—	$-0.00	—	—
Q4 2019	Dec 30, 2019	—	$-0.00	—	—

Frequently Asked Questions about CHMMF

What is CHMMF's current stock price?

Chimeric Therapeutics Limited (CHMMF) is currently trading at $0.00 per share. The stock has moved +0.00% today.

What is the analyst price target for CHMMF?

No analyst price targets are currently available for this stock.

What sector is Chimeric Therapeutics Limited in?

Chimeric Therapeutics Limited operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the OTC exchange.

What is CHMMF's market cap?

Chimeric Therapeutics Limited has a market capitalization of $0.00 billion, making it a small-cap company.

Does CHMMF pay dividends?

No, Chimeric Therapeutics Limited does not currently pay a dividend to shareholders.